Targeting EGFR in Esophagogastric Cancer
Esophagogastric cancer (EGC) remains a major cause of cancer-related mortality. Overall survival in the metastatic setting remains poor, with few molecular targeted approaches having been successfully incorporated into routine care to-date: only first line anti-HER2 therapy in ERBB2-expressing tumor...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.553876/full |
| _version_ | 1818880343032201216 |
|---|---|
| author | Steven B. Maron James Xu Yelena Y. Janjigian |
| author_facet | Steven B. Maron James Xu Yelena Y. Janjigian |
| author_sort | Steven B. Maron |
| collection | DOAJ |
| description | Esophagogastric cancer (EGC) remains a major cause of cancer-related mortality. Overall survival in the metastatic setting remains poor, with few molecular targeted approaches having been successfully incorporated into routine care to-date: only first line anti-HER2 therapy in ERBB2-expressing tumors, second line anti-VEGFR2 therapy with ramucirumab in unselected patients, and pembrolizumab in PD-L1 expressing or MSI-H patients. EGFR inhibitors were extensively studied in EGC, including phase III trials with cetuximab (EXPAND), panitumumab (REAL3), and gefitinib (COG). All three trials were conducted in unselected populations, and therefore, failed to demonstrate clinical benefit. Here, we review previous attempts at targeting EGFR in EGC and potential future biomarkers for targeting this pathway in patients with EGFR-amplified tumors. |
| first_indexed | 2024-12-19T14:44:27Z |
| format | Article |
| id | doaj.art-d6715a335f934cd9b420ce3bf5e3f9c1 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-19T14:44:27Z |
| publishDate | 2020-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d6715a335f934cd9b420ce3bf5e3f9c12022-12-21T20:17:00ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-12-011010.3389/fonc.2020.553876553876Targeting EGFR in Esophagogastric CancerSteven B. Maron0James Xu1Yelena Y. Janjigian2Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United StatesComputer Engineering Program, Columbia University, New York, NY, United StatesGastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United StatesEsophagogastric cancer (EGC) remains a major cause of cancer-related mortality. Overall survival in the metastatic setting remains poor, with few molecular targeted approaches having been successfully incorporated into routine care to-date: only first line anti-HER2 therapy in ERBB2-expressing tumors, second line anti-VEGFR2 therapy with ramucirumab in unselected patients, and pembrolizumab in PD-L1 expressing or MSI-H patients. EGFR inhibitors were extensively studied in EGC, including phase III trials with cetuximab (EXPAND), panitumumab (REAL3), and gefitinib (COG). All three trials were conducted in unselected populations, and therefore, failed to demonstrate clinical benefit. Here, we review previous attempts at targeting EGFR in EGC and potential future biomarkers for targeting this pathway in patients with EGFR-amplified tumors.https://www.frontiersin.org/articles/10.3389/fonc.2020.553876/fullesophageal cancergastric cancergastroesophageal cancerepidermal growth factor receptorcetuximabpanitumumab |
| spellingShingle | Steven B. Maron James Xu Yelena Y. Janjigian Targeting EGFR in Esophagogastric Cancer Frontiers in Oncology esophageal cancer gastric cancer gastroesophageal cancer epidermal growth factor receptor cetuximab panitumumab |
| title | Targeting EGFR in Esophagogastric Cancer |
| title_full | Targeting EGFR in Esophagogastric Cancer |
| title_fullStr | Targeting EGFR in Esophagogastric Cancer |
| title_full_unstemmed | Targeting EGFR in Esophagogastric Cancer |
| title_short | Targeting EGFR in Esophagogastric Cancer |
| title_sort | targeting egfr in esophagogastric cancer |
| topic | esophageal cancer gastric cancer gastroesophageal cancer epidermal growth factor receptor cetuximab panitumumab |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2020.553876/full |
| work_keys_str_mv | AT stevenbmaron targetingegfrinesophagogastriccancer AT jamesxu targetingegfrinesophagogastriccancer AT yelenayjanjigian targetingegfrinesophagogastriccancer |